<DOC>
	<DOCNO>NCT02531009</DOCNO>
	<brief_summary>The primary objective study assess change systemic sclerosis ( SSc ) -associated gastrointestinal ( GI ) tract symptoms 1-year period participant SSc .</brief_summary>
	<brief_title>Systemic Sclerosis Clinical Biomarker Study</brief_title>
	<detailed_description>No study treatment administer . Study participant continue treat respective physician accord standard clinical practice . Data concomitant therapy procedure , administer part standard care , collect baseline study visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Key Healthy volunteer Must good health determine Investigator , base medical history , physical examination , vital sign . Participants diffuse cutaneous systemic sclerosis ( dcSSc ) : Must fulfill 2013 classification criterion SSc American College Rheumatology ( ACR ) European League Against Rheumatism ( EULAR ) . Absence anticentromere autoantibody . Participants limit cutaneous systemic sclerosis ( lcSSc ) : Must fulfill 2013 classification criterion SSc ACR EULAR . Subjects lcSSc must disease duration less 5 year . Key History clinically significant medical condition interfere conduct study , opinion Investigator , would compromise data interpretation . An active severe infection determine Investigator . Female subject pregnant currently breastfeed . A known history malignancy . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>